CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer
Top Cited Papers
- 20 May 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Medicine
- Vol. 27 (7), 1280-1289
- https://doi.org/10.1038/s41591-021-01386-7
Abstract
Patients with cancer have high mortality from coronavirus disease 2019 (COVID-19), and the immune parameters that dictate clinical outcomes remain unknown. In a cohort of 100 patients with cancer who were hospitalized for COVID-19, patients with hematologic cancer had higher mortality relative to patients with solid cancer. In two additional cohorts, flow cytometric and serologic analyses demonstrated that patients with solid cancer and patients without cancer had a similar immune phenotype during acute COVID-19, whereas patients with hematologic cancer had impairment of B cells and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific antibody responses. Despite the impaired humoral immunity and high mortality in patients with hematologic cancer who also have COVID-19, those with a greater number of CD8 T cells had improved survival, including those treated with anti-CD20 therapy. Furthermore, 77% of patients with hematologic cancer had detectable SARS-CoV-2-specific T cell responses. Thus, CD8 T cells might influence recovery from COVID-19 when humoral immunity is deficient. These observations suggest that CD8 T cell responses to vaccination might provide protection in patients with hematologic cancer even in the setting of limited humoral responses.Keywords
This publication has 70 references indexed in Scilit:
- Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in ChinaJAMA, 2020
- Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, ChinaClinical Infectious Diseases, 2020
- Pathological findings of COVID-19 associated with acute respiratory distress syndromeThe Lancet Respiratory Medicine, 2020
- Department of ErrorThe Lancet, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- Earth Mover’s Distance (EMD): A True Metric for Comparing Biomarker Expression Levels in Cell PopulationsPLOS ONE, 2016
- Performance Status in Patients With CancerJAMA Oncology, 2015
- Dexamethasone co-medication in cancer patients undergoing chemotherapy causes substantial immunomodulatory effects with implications for chemo-immunotherapy strategiesOncoImmunology, 2015
- Standardizing immunophenotyping for the Human Immunology ProjectNature Reviews Immunology, 2012
- CD8+ T lymphocyte-mediated antiviral immunity in mice as a result of injection of recombinant viral proteins.The Journal of Immunology, 1994